Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Lonafarnib in Metastatic Breast Cancer

21. januar 2016 oppdatert av: George Sledge

A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer

A published phase 2 study reported that lonafarnib was administered as a single agent via continuous or intermittent oral dosing to 76 women with advanced breast cancer who were previously treated with chemotherapy and/or with endocrine therapy. Objective response rates of approximately 10% were observed. This study will determine the rate of progression-free survival of patients with metastatic breast cancer who receive lonafarnib.

Studieoversikt

Status

Avsluttet

Intervensjon / Behandling

Detaljert beskrivelse

OUTLINE: This is a multi-center study

Patients will be treated with lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.

1 Cycle = 21 days of lonafarnib (plus the time required to recover from toxicity if encountered).

ECOG Performance Status 0-1

Life Expectancy: Not Specified

Hematopoietic:

  • Platelets > 100 K/mm3
  • Absolute Neutrophil Count (ANC) > 1.2 K/mm3
  • Hemoglobin ≥ 9 g/dl
  • Serum potassium ≥ 3.3 mmol/L

Hepatic:

  • Aspartate transaminase (AST) ≤ 5.0 x ULN
  • Alanine transaminase (ALT) ≤ 5.0 x ULN
  • Total bilirubin < 1.5 x ULN

Renal:

  • Calculated creatinine clearance (using Cockcroft-Gault formula) > 45 cc/min

Cardiovascular:

  • No history of Torsades de Pointes, ventricular tachycardia, ventricular fibrillation or ventricular flutter

Studietype

Intervensjonell

Registrering (Faktiske)

29

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Illinois
      • Galesburg, Illinois, Forente stater, 61401
        • Medical & Surgical Specialists, LLC
    • Indiana
      • Bloomington, Indiana, Forente stater, 47403
        • Cancer Care Center of Southern Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University Melvin and Bren Simon Cancer Center
      • Lafayette, Indiana, Forente stater, 47905
        • Horizon Oncology Center
      • Lafayette, Indiana, Forente stater, 47904
        • Arnett Cancer Care
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Ireland Cancer Center - University Hospitals of Cleveland

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histological or cytological confirmed adenocarcinoma of the breast with locally advanced or metastatic disease.
  • Must be able and willing to enroll in the companion study entitled "Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-03."
  • Must have measurable disease per RECIST as evaluated by imaging within 28 days prior to registration for protocol therapy.
  • Must be willing to not drink grapefruit juice for the duration of lonafarnib therapy.
  • Previously radiated area(s) must not be the only site of disease for study entry.
  • Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time of consent until at least 90 days following completion of study treatment.
  • Females of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy. Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
  • Females must not be breastfeeding.
  • Written informed consent and HIPAA authorization for release of personal health information.
  • Age > 18 years

Exclusion Criteria:

  • No history or radiologic evidence of CNS metastases including previously treated, resected or asymptomatic brain lesions or leptomeningeal involvement (head CT or MRI must be obtained within 42 days prior to registration for protocol therapy).
  • No treatment with any investigational agent within 30 days prior to registration for protocol therapy.
  • No history of Torsades de Pointes, ventricular tachycardia, ventricular fibrillation or ventricular flutter.
  • No history of syncope.
  • No history of seizures.
  • No prolonged QTc interval > 450msec on pre-entry electrocardiogram obtained within 28 days prior to registration for protocol therapy.
  • No history of hypokalemia that cannot be corrected prior to registration for protocol therapy.
  • No radiation within 14 days prior to registration for protocol therapy. Patients must have recovered from the acute toxic effects prior to registration for protocol therapy.
  • No prior chemotherapy within 21 days prior to registration for protocol therapy.
  • No clinically active serious infections as judged by the treating investigator (CTC v3, > Grade 2) including known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
  • Following concomitant medications must be discontinued 7 days prior to registration for protocol therapy and for the duration of lonafarnib therapy: bisphosphonates, including but not limited to etidronate (Didronel), pamidronate (Aredia), alendronate (Fosamax), risedronate (Actonel), zoledronate (Zometa or Reclast), ibandronate (Boniva), ethinylestradiol, gestodene, itraconazole, ketoconazole, cimetidine, erythromycin, carbamazepine, high dose chronic steroids, phenobarbital, phenytoin, rifampin (rifampicin), sulfinpyrazone

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Lonafarnib
All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression Free Survival
Tidsramme: 18 months
To determine progression-free survival of lonafarnib in patients with metastatic breast cancer.
18 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response Rate
Tidsramme: 18 months
To determine overall response rate.
18 months
Toxicity Profile of Lonafarib
Tidsramme: 18 months
To determine the toxicity profile of lonafarnib in this patient population.
18 months
Clinical Benefit Response Rate (Complete Response (CR)+Partial Response(PR)+Stable Disease(SD) > 180 Day Duration).
Tidsramme: 18 months
18 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: George Sledge, M.D., Hoosier Cancer Research Network
  • Hovedetterforsker: Brian Leland-Jones, M.D., Hoosier Cancer Research Network

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2008

Primær fullføring (Faktiske)

1. november 2010

Studiet fullført (Faktiske)

1. november 2010

Datoer for studieregistrering

Først innsendt

14. oktober 2008

Først innsendt som oppfylte QC-kriteriene

14. oktober 2008

Først lagt ut (Anslag)

16. oktober 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

18. februar 2016

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. januar 2016

Sist bekreftet

1. januar 2016

Mer informasjon

Begreper knyttet til denne studien

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere